-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EgVer+1mHHkjzL7W3b4ju+yfkXTCJQ8LWuLLOD9JliZ0pI+ojHRtKnN15n3S8SK+
 sz4w40a+/KJq9IxxLNBzPw==

<SEC-DOCUMENT>0001181431-04-061025.txt : 20041229
<SEC-HEADER>0001181431-04-061025.hdr.sgml : 20041229
<ACCEPTANCE-DATETIME>20041229105016
ACCESSION NUMBER:		0001181431-04-061025
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041229
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041229
DATE AS OF CHANGE:		20041229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COTHERIX INC
		CENTRAL INDEX KEY:			0001138812
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50794
		FILM NUMBER:		041229734

	BUSINESS ADDRESS:	
		STREET 1:		5000 SHORELINE COURT
		STREET 2:		SUITE 101
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-808-6500

	MAIL ADDRESS:	
		STREET 1:		5000 SHORELINE COURT
		STREET 2:		SUITE 101
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXHALE THERAPEUTICS INC
		DATE OF NAME CHANGE:	20010503
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rrd62810.htm
<DESCRIPTION>GRYSKA
<TEXT>



<HTML>


<HEAD>








<TITLE> </TITLE>


<META NAME="_AdHocReviewCycleID" CONTENT="-1211988673">


<META NAME="_EmailSubject" CONTENT="David Gryska D&amp;O Q">


<META NAME="_AuthorEmail" CONTENT="abowdidge@cotherix.com">


<META NAME="_AuthorEmailDisplayName" CONTENT="Anne Bowdidge">


<META NAME="_PreviousAdHocReviewCycleID" CONTENT="-1048441825">


<META NAME="Template" CONTENT="Normal">


</HEAD>


<BODY LINK="#0000ff" VLINK="#800080" BGCOLOR="#ffffff">





<FONT SIZE=2>


<B><P ALIGN="CENTER">&nbsp;</P>


<P ALIGN="CENTER">UNITED STATES </P>


<P ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION </P>


</B><P ALIGN="CENTER">Washington, D.C. 20549 </P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="CENTER">________________________</P>


</FONT><B><FONT SIZE=4><P ALIGN="CENTER">FORM 8K </P>


</B></FONT><FONT SIZE=2><P ALIGN="CENTER">________________________</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="CENTER">CURRENT REPORT</P>


<P ALIGN="JUSTIFY"></P><DIR>





<P ALIGN="CENTER">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </P>


<P ALIGN="CENTER"></P>


<P ALIGN="CENTER">Date of report (date of earliest event reported):  December 29, 2004</P>


<P ALIGN="JUSTIFY"></P></DIR>





</FONT><B><FONT SIZE=5 COLOR="#808080"><P ALIGN="CENTER">CoTherix, Inc.</P>


</B></FONT><FONT SIZE=2><P ALIGN="CENTER">(Exact name of registrant as specified in its charter) </P>


<P ALIGN="JUSTIFY"></P></FONT>


<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=716>


<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=14><DIR>





<B><FONT SIZE=2><P>&#9;&#9;Delaware</DIR>


</B></FONT></TD>


<TD WIDTH="22%" VALIGN="TOP" HEIGHT=14>


<B><FONT SIZE=2><P ALIGN="CENTER">000-05794</B></FONT></TD>


<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=14>


<B><FONT SIZE=2><P ALIGN="CENTER">04-3513144</B></FONT></TD>


</TR>


<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=15><DIR>





<FONT SIZE=2><P ALIGN="CENTER">(State or other jurisdiction of incorporation or organization)</DIR>


</FONT></TD>


<TD WIDTH="22%" VALIGN="TOP" HEIGHT=15>


<FONT SIZE=2><P ALIGN="CENTER">(Commission File Number)</FONT></TD>


<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=15>


<FONT SIZE=2><P ALIGN="CENTER">(I.R.S. employer identification number)</FONT></TD>


</TR>


</TABLE>


</CENTER></P>





<FONT SIZE=2><P ALIGN="JUSTIFY"></P>


<B><P ALIGN="CENTER">5000 Shoreline Court, Suite 101, South San Francisco, CA 94080</P>


</B><P ALIGN="CENTER">(Address of principal executive offices and zip code) </P>


<P ALIGN="JUSTIFY"></P>


<B><P ALIGN="CENTER">(650) 808-6500 </P>


</B><P ALIGN="CENTER">(Registrant's telephone number, including area code) </P>


<P ALIGN="JUSTIFY"></P>


<P>&nbsp;</P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<B><P ALIGN="RIGHT"><A NAME="toc"></A></P>


<P ALIGN="RIGHT"></P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P>Item 5.02.&nbsp; Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers</P>


</B>


<P ALIGN="JUSTIFY">Effective December 28, 2004, Mr. David Gryska was elected to serve as a director of CoTherix, Inc (the &quot;Company&quot;).  As of the same date, Mr. Gryska was appointed as a member of the Company's Audit Committee, and he will initially serve as the chairman of the Audit Committee.  A copy of the related press release is furnished as Exhibit 99.1 to this Current Report.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">From November 2000 to October 2004, Mr. Gryska served as Senior Vice President and Chief Financial Officer of Scios Inc., a biopharmaceutical company, and from December 1998 to November 2000, he was Vice President of Finance and Chief Financial Officer of Scios Inc.  From 1993 to December 1998, Mr. Gryska was Vice President, Finance and Chief Financial Officer of Cardiac Pathways Corporation, a medical device company.  Mr. Gryska was with Ernst &amp; Young LLP from 1982 to 1993 and served as a partner from 1989 to 1993.  Mr. Gryska holds a B.A. in accounting and a B.A. in finance from Loyola University of Chicago and an M.B.A. from Golden Gate University.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">Pursuant to the Company's automatic option grant program for non-employee directors under the Company's 2004 Equity Incentive Plan, Mr. Gryska was granted an option to purchase 18,180 shares of the Company's Common Stock.  The exercise price per share is equal to the fair market value per share on the date the option was granted.  Mr. Gryska will vest in 1/12 of the option shares upon his completion of each three-month period of continuous service with the Company.  Vesting accelerates under certain circumstances.</P>


<P ALIGN="JUSTIFY">Also pursuant to the Company's automatic option grant program, starting in 2005, Mr. Gryska will receive an option to purchase 6,060 shares of the Company's Common Stock at each regular annual meeting of the Company's stockholders for a three-year period, provided that he continues to be a Board member.  Starting in his fifth year of Board service, this annual option grant will cover 9,090 shares of the Company's Common Stock.  The exercise price per share of each option will be equal to the fair market value per share on the date such option is granted.  For each of these annual option grants, he will vest in 1/4 of the option shares upon his completion of each three-month period of continuous service with the Company.  Vesting accelerates under certain circumstances.</P>


<B><P ALIGN="JUSTIFY">Item 9.01.  Financial Statements and Exhibits</P>


<P ALIGN="JUSTIFY"></P>


</B><P ALIGN="JUSTIFY">(c)  Exhibits</P>


<P ALIGN="JUSTIFY"></P>


<OL>


<OL>





<P ALIGN="JUSTIFY"><LI>Press Release of CoTherix, Inc. dated December 29, 2004 regarding the election of Mr. David Gryska as a member of the Company's Board of Directors, furnished in accordance with Item 5.02 of this Current Report.</LI></P></OL>


</OL>





<B><P ALIGN="JUSTIFY"></P>


</B><P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="JUSTIFY">The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed &quot;filed&quot; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<B><P ALIGN="CENTER">SIGNATURES </P>


</B><P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">Date:  December 29, 2004</P></FONT>


<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=288>


<TR><TD VALIGN="BOTTOM" COLSPAN=2>


<B><FONT SIZE=2><P>CoTherix, Inc.</B></FONT></TD>


</TR>


<TR><TD WIDTH="9%" VALIGN="TOP">


<FONT SIZE=2><P>By: </FONT><FONT SIZE=1>&nbsp;</FONT></TD>


<TD WIDTH="91%" VALIGN="BOTTOM">


<FONT SIZE=2><P>/s/ Christine Gray-Smith</FONT></TD>


</TR>


<TR><TD VALIGN="TOP" COLSPAN=2 HEIGHT=55>


<FONT SIZE=2><P ALIGN="JUSTIFY">Christine Gray-Smith</P>


<P ALIGN="JUSTIFY">Executive Vice President and Chief Financial Officer</P>


</FONT></TD>


</TR>


</TABLE>


</P>





<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="CENTER">&nbsp;</P>


<B><P ALIGN="CENTER">INDEX TO EHXIBITS FILED WITH</P>


<P ALIGN="CENTER">THE CURRENT REPORT ON FORM 8-K DATED DECEMBER 29, 2004</P>


<P ALIGN="CENTER"></P>


<U><P>Exhibit&#9;</U>&#9;&#9;<U>Description</P>


</U><DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>





</B><P>99.1&#9;Press Release of CoTherix, Inc. dated December 29, 2004 regarding the election of Mr. David Gryska as a member of the Company's Board of Directors, furnished in accordance with Item 5.02 of this Current Report on Form 8-K.</P>


<B><P ALIGN="RIGHT"></P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P></DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</B></FONT></BODY>


</HTML>









</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rrd62810_2636.htm
<DESCRIPTION>GRYSKA
<TEXT>



<HTML>


<HEAD>








<TITLE>FOR IMMEDIATE RELEASE</TITLE>


<META NAME="_AdHocReviewCycleID" CONTENT="383577084">


<META NAME="_EmailSubject" CONTENT="Gryska Appointment">


<META NAME="_AuthorEmail" CONTENT="abowdidge@cotherix.com">


<META NAME="_AuthorEmailDisplayName" CONTENT="Anne Bowdidge">


<META NAME="_PreviousAdHocReviewCycleID" CONTENT="-1066340110">


</HEAD>


<BODY>





<B><FONT FACE="Times New Roman Bold"><P>Exhibit 99.1</P>


<U>


<P>FOR IMMEDIATE RELEASE</P>


</B></U></FONT>


<U><P>&nbsp;</P>


<P>Investor and Media Contact:</P>


</U><P>Anne Bowdidge<BR>


Senior Director of Investor Relations</P>


<P>650-808-6551</P>





<P>&nbsp;</P>


<P>&nbsp;</P>


<P>&nbsp;</P>


<B><FONT FACE="Times New Roman Bold"><P>&nbsp;</P><DIR>


<DIR>


<DIR>


<DIR>





</FONT><FONT FACE="Times New Roman Bold" SIZE=4><P ALIGN="CENTER">CoTherix, Inc. Appoints David Gryska to Board of Directors</P>


</B></FONT><P ALIGN="JUSTIFY"></P></DIR>


</DIR>


</DIR>


</DIR>





<B><P ALIGN="JUSTIFY">South San Francisco, Calif., </B>December 29, 2004.  CoTherix, Inc. (Nasdaq: CTRX) today announced that David Gryska has been elected to the Company's Board of Directors.  Mr. Gryska will also serve as Chairman of the Audit Committee. </P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&quot;We are pleased to welcome Dave to our Board of Directors,&quot; said Donald J. Santel, Chief Executive Officer of CoTherix, Inc.  &quot;Dave brings a wealth of financial and operating experience in the biopharmaceutical industry, and a track record of success at Scios, which will add direct and immediate value to the CoTherix team.&quot;</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&quot;CoTherix is going through a very exciting evolution as it seeks to introduce Ventavis Inhalation Solution, a non-invasive therapy for the treatment of pulmonary arterial hypertension,&quot; said Mr. Gryska.  &quot;I look forward to working with the CoTherix Board and experienced senior management team as they execute the clinical and commercial activities necessary to fully capitalize on this opportunity.&quot;   </P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">Most recently, Mr. Gryska served as Senior Vice President and Chief Financial Officer at Scios, Inc., where he led the transaction effort for the successful sale of the company to Johnson &amp; Johnson for $2.5 billion in February 2003.  Prior to Scios, he served as Vice President and Chief Financial Officer at Cardiac Pathways, a company later acquired by Boston Scientific Corporation.  He also served as a partner at Ernst &amp; Young, with an emphasis on biotechnology and healthcare companies.  </P>


<P ALIGN="JUSTIFY"></P>


<B><P ALIGN="JUSTIFY">About CoTherix, Inc.</P>


<P ALIGN="JUSTIFY"></P>


</B><P ALIGN="JUSTIFY">CoTherix Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases.  CoTherix' lead product candidate, Ventavis&trade;, is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins.  CoTherix is developing Ventavis for the treatment of pulmonary arterial hypertension, a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs.  Ventavis is currently marketed in various European countries and Australia by Schering AG.  CoTherix licensed the exclusive United States rights to Ventavis from Schering AG in October 2003.  CoTherix and the CoTherix logo are trademarks of CoTherix, Inc.  Ventavis is a trademark of Schering AG, Germany.  More information can be found at www.cotherix.com.</P>


<P ALIGN="JUSTIFY"></P>


<B><P ALIGN="JUSTIFY">Forward-Looking Statements</P>


</B><P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, intentions or strategies.  All forward-looking statements included in this press release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise.  Our actual results could differ materially from our current expectations.  Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the Securities and Exchange Commission, including our current report on Form 10-Q for the quarter ended September 30, 2004.  </P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="CENTER">###</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&nbsp;</P></BODY>


</HTML>









</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
